Akebia Ther Stock Investor Sentiment

AKBA Stock  USD 2.40  0.14  6.19%   
About 68 percent of all Akebia Ther's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Akebia Ther suggests that a large number of traders are confidant. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
  

Akebia Ther Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Akebia Ther Maximum Pain Price Across April 17th 2025 Option Contracts

Akebia Ther's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Akebia Ther close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Akebia Ther's options.
over six months ago at finance.yahoo.com         
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over six months ago at news.google.com         
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 - Barchart
Google News at Macroaxis
over six months ago at finance.yahoo.com         
When Can We Expect A Profit From Akebia Therapeutics, Inc.?
Yahoo News
over six months ago at news.google.com         
Akebia Therapeutics Enterprise Value 265.1 Mil - GuruFocus.com
Google News at Macroaxis
over six months ago at news.google.com         
Akebia Therapeutics Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies Canada
Google News at Macroaxis
over six months ago at news.google.com         
Akebia Therapeutics Reports Q4 Loss, Misses Revenue Estimates - Yahoo Movies UK
Google News at Macroaxis
over six months ago at news.google.com         
Sapient Capital LLC Buys Shares of 200000 Akebia Therapeutics, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Is Akebia Therapeutics Stock Outpacing Its Medical Peers This Year - Yahoo Movies UK
Google News at Macroaxis
over six months ago at news.google.com         
Akebia Therapeutics Surpasses Q2 Earnings and Revenue Estimates - Yahoo Movies UK
Google News at Macroaxis
over six months ago at news.google.com         
Akebia Therapeutics Upgraded by StockNews.com to Buy - Defense World
Google News at Macroaxis
over six months ago at investing.com         
H.C. Wainwright lifts Akebia shares target following FDA approval
Investing News at Macroaxis
over six months ago at benzinga.com         
FDA Approves For Akebia Therapeutics Vafseo For Kidney Disease Associated Anemia
benzinga news
over six months ago at statnews.com         
How GLP-1s moved from research labs to national TV
news
over six months ago at zerohedge.com         
Stocks Set To Close Blowout Week, Month And Quarter At All-Time High Gold Soars To Record
news
over six months ago at finance.yahoo.com         
UPDATE 1-U.S. FDA approves Akebias anemia drug
Yahoo News
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Ther Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 20100 shares by Frieson Ron of Akebia Ther at 0.45 subject to Rule 16b-3
01/17/2025
2
Acquisition by Ostrowski Erik of 292300 shares of Akebia Ther at 2.24 subject to Rule 16b-3
01/31/2025
3
Disposition of 55621 shares by Nicholas Grund of Akebia Ther at 2.1 subject to Rule 16b-3
02/03/2025
4
Akebia Therapeutics NASDAQAKBA investor five-year losses grow to 80 percent as the stock sheds US55m this past week
02/26/2025
5
Disposition of 7144 shares by Steven Burke of Akebia Ther at 1.83 subject to Rule 16b-3
03/03/2025
6
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
03/04/2025
7
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024Financial Results and Discuss Recent Business Highlights
03/06/2025
8
Akebia Therapeutics Projected to Post Quarterly Earnings on Thursday
03/12/2025
9
Akebia GAAP EPS of -0.10 misses by 0.02, revenue of 46.49M beats by 9.13M
03/13/2025
10
Akebia Therapeutics Inc Q4 2024 Earnings Call Highlights Navigating Revenue Declines ...
03/14/2025

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Stocks Directory
Find actively traded stocks across global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Transaction History
View history of all your transactions and understand their impact on performance